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The human Vg9Vδ2 T cells are a unique T cell type,
and recent studies of the biology of Vg9Vδ2 T cells
emphasize the potential exploitation of these cells in
immunotherapy of cancer. Vg9Vδ2 T cells exhibit dual
functionality in that they are both antigen presenting
cells (APC) and cytotoxic towards cancer cells. We
show that Vg9Vδ2 T cells can kill cancer cell lines from
various cancer types such as leukemia, melanoma, pros-
tate-, and breast cancer, with a significantly increased
killing upon treatment of the cancer cells with Zoledronic
acid. In addition, we show that Vg9Vδ2 T cells take up
tumor antigens gp100 and MART-1 (long peptide and
recombinant protein, respectively), and process these anti-
gens for presentation of class I restricted peptides in the
context of the HLA-A02.01 molecule, to be recognized by
peptide specific cytotoxic CD8 T cells. Moreover, we show
that specific inhibition of the proteasome by lactacystin
impair recognition by peptide specific CD8 T cells,
strongly suggesting proteasome involvement in presenta-
tion of the relevant class I restricted peptides. The dual
functions; killing and antigen presentation combined with
the ease of expanding Vg9Vδ2 T cells in vitro from periph-
eral blood lymphocytes to billions of cells, makes Vg9Vδ2
T cells attractive vehicles for adoptive cell therapy (ACT)
in cancer therapy. Thus, Vg9Vδ2 T cells are broadly
tumor specific killers, that concurrently could induce or
support tumor specific ab-T cell responses.
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